Inacutemyeloidleu-kemia,thepercentofexpressioninCD117,CD13andCD33was91.9%、91.6%and94.4%.Theseweresignificantlyhighercomparedwithacutelymphoblasticleukemia(P<0.01);Conclusion:CD117,CD13andCD33mightbesignificantindifferentialdiagnosisbetweenacutemyeloidleukemiaandacutelymphoblasticleukemia.Key words:Acutemyeloidleukemia...
Extraordinarily elevated CD33 expression in CD56+CD3– cells in the bone marrow of a patient with relapsed acute myeloid leukemia: a case reportCase reportnatural killer (NK) cellsallogeneic stem cell transplantation (allo-SCT)acute myeloid leukemia (AML)...
CD33low blasts are associated to a more mature AML and its high expression is related to adverse landscapes in pediatric AML, highlighting the importance of CD33 evaluation. Regarding vulnerable steps of MRD assessment, Post –analytical phase must embrace a set of standards in order to prevent ...
CD33 mRNA expression is specifically increased in microglia, and expression in autopsy brain tissue is associated with more advanced cognitive decline (Bradshaw et al., 2013; Jiang et al., 2014). Aβ phagocytosis is inhibited in microglial cells overexpressing CD33 (Griciuc et al., 2013), and...
Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger; CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood 2021; 137 (8): 1037–1049. doi: https://doi.org/10.1182/blood.202...
The ADC BL-M11D1 is a CD33 specific antibody based on the drug Gemtuzumab.Due to its CD33 binding, BL-M11D1 has specificity toward CD33 expression hematopoietic malignancies including AML.The BL-M11D1 is engineered to have an IgG wt FC receptor allowing for the mediation of innate ...
A number of single nucleotide polymorphisms (SNPs) have been identified in AML patients that influence the effectiveness of gemtuzumab ozogamicin immunotherapy. SNP rs12459419 C>T in the splice enhancer region present in exon2 regulates the expression of an alternatively spliced CD33 isoform lacking ...
In addition, CD33 is also involved in other processes, such as adhesion (1-3). Due to its exclusive expression on hematopoietic cells, particularly the myeloid lineage and their progenitors, CD33 has been actively pursued as a therapeutic target against acute myeloid leukemia (AML) (4,5). ...
目的探讨抗CD33单抗吉妥单抗治疗由复发难治急性髓系白血病(RR-AML)转化的混合表型急性白血病(MPAL)患者的效果及预后。 方法回顾性分析苏州大学附属第一医院诊治的1例由RR-AML转化的MPAL(B淋系和髓系双表型)患者的临床资料,并复习相关文献。 结果该患者采用吉妥单抗3 mg/m 2第1、5、9天联合三尖杉酯碱、小剂量...
的AML 患者的白血病原始细胞表面表达CD33,而 造血干细胞,淋巴细胞及非造血细胞不表达J.人 源化的抗CD33mAb 与毒素相连而成的药物美罗泰 格已经被美国FDA 批准上市.由于鼠源性抗体因 具有较强的免疫原性,应用于人体时会产生强烈的 人抗鼠抗体反应,因此严重限制了其在临床的应用; scFv 是由接头(1inker...